Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians

Many Adults With CVD Treated With High-Intensity Statins Are Not Achieving Recommended LDL-C Levels

PINNACLE: Rates of LLT Use Among Patients With LDL-C ≥ 190 mg/dL

PCSK9 Inhibitor CV Outcomes Trials

FOURIER CV Outcomes

ODYSSEY CV Outcomes

ODYSSEY Subgroup With Baseline LDL-C ≥ 100 mg/dL

ICER Alirocumab Effectiveness and Value

PCSK9 Inhibitor Valuation

PCSK9 Inhibitor Safety Data

Patients Who May Benefit From PCSK9 Inhibitor Therapy 2017 Focused Update of 2016 ACC Expert Consensus Decision Pathway on Role of Non-Statin Therapies

FOCUS: PCSK9 Inhibitor Rejection Rate in Patients With FH or ASCVD

CV Risk in Patients Denied PCSK9 Inhibitor Therapy

2017 Focused Update of 2016 ACC Expert Consensus Decision Pathway: Role of Nonstatin Therapies in LDL-C Lowering

Tools for Assisting PCSK9 Inhibitor Access

Barriers to PSCK9 Inhibitor Access

Navigating the Prior Authorization Process Clinical Pearls

Universal Guidance for Improving Access to PCSK9 Inhibitors

Team-Based Care

AHA Diagnostic Criteria for FH in Adults

FH Foundation Guidance: Prior Authorization Criteria for PCSK9 Inhibitors for FH Treatment in Adults

Case: 65-Year-Old Man With CAD Post-CABG

Case: 65-Year-Old Man With CAD Post-CABG (cont) Initial Treatment Plan

Case: 65-Year-Old Man With CAD Post-CABG (cont) Muscle Symptoms With Atorvastatin

Case: 65-Year-Old Man With CAD Post-CABG (cont) Rosuvastatin Intolerability

Patient Education PCSK9 Inhibitor Therapy

Patient Education Correct Injecting Procedure

Summary

Abbreviations

Abbreviations (cont)